Evidence map›Paper›PMID 31758224›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2020

Fadi Khreish, Niklas Ebert, Martin Ries, Stephan Maus, Florian Rosar, Hendrik Bohnenberger, Tobias Stemler, Matthias Saar, Mark Bartholomä, Samer Ezziddin

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 126 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
126citing papers in PubMed, 9 pooled it
15.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

126 citing papers in PubMed, 9 syntheses or guidelines pooled it, 210 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Beyond [BMC cancer · 2026
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Evaluating Xerostomia as a side effect of [European journal of nuclear medicine and molecular imaging · 2025
    Pooled it
  7. Efficacy and Safety ofFrontiers in oncology · 2022
    Pooled it
  8. Evolving role ofProstate cancer and prostatic diseases · 2021
    Pooled it
  9. Pooled it
  10. Trial
  11. Article
  12. Targeted Radionuclide Therapy: Current Landscape and Combination Approaches to Improve Oncology Outcomes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Review
  13. Observational
  14. Review
  15. Review
  16. Observational
  17. Remarkable response after cocktail therapy withEuropean journal of nuclear medicine and molecular imaging · 2026
    Article
  18. Article
  19. Article
  20. Refining the clinical utility of [European journal of nuclear medicine and molecular imaging · 2026
    Article

66 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Fadi KhreishDepartment of Nuclear Medicine, Saarland University, 66421, Homburg, Germany.
Niklas EbertDepartment of Nuclear Medicine, Saarland University, 66421, Homburg, Germany.
Martin RiesDepartment of Nuclear Medicine, Saarland University, 66421, Homburg, Germany.
Stephan MausDepartment of Nuclear Medicine, Saarland University, 66421, Homburg, Germany.
Florian RosarDepartment of Nuclear Medicine, Saarland University, 66421, Homburg, Germany.
Hendrik BohnenbergerDepartment of Nuclear Medicine, Saarland University, 66421, Homburg, Germany.
Tobias StemlerDepartment of Nuclear Medicine, Saarland University, 66421, Homburg, Germany.
Matthias SaarDepartment of Urology, Saarland University, 66421, Homburg, Germany.
Mark BartholomäDepartment of Nuclear Medicine, Saarland University, 66421, Homburg, Germany.
Samer EzziddinDepartment of Nuclear Medicine, Saarland University, 66421, Homburg, Germany. samer.ezziddin@uks.eu.ORCID 0000-0003-4110-3375
Saarland University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeUp to 30% of patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) never respond or develop resistance to

methodsWe retrospectively analyzed pilot experience with 1 course of

resultsMedian (minimum-maximum) administered activities were

conclusionsOur results suggest that a single course of tandem therapy with low-activity

Indexed as

Prostatic Neoplasms, Castration-ResistantActiniumDipeptidesHeterocyclic Compounds, 1-RingHumansMaleProstate-Specific AntigenRadiopharmaceuticalsRetrospective StudiesTreatment Outcome(225)Ac-PSMA-617ActiniumDipeptidesHeterocyclic Compounds, 1-RingProstate-Specific AntigenPSMA-617Radiopharmaceuticals177Lu-PSMA-617 therapy225Ac-PSMA-617 therapyCombination PSMA radioligand therapyMetastatic castration-resistant prostate cancerTandem PSMA radioligand therapyXerostomia

Identifiers

PMID31758224
OpenAlexW2990351859

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.